Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

Restless Legs Syndrome Clinical Trial

Official title:

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pramipexole With the Dose Range From 0.125 mg to 0.75 mg Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00152997
• Other study ID #: 248.557
• Status: Completed
• Phase: Phase 2
• First received: September 9, 2005
• Last updated: October 30, 2013
• Start date: August 2004

Study information

• Verified date: October 2013
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and WelfareUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objective of this trial is to investigate the efficacy and safety of pramipexole (0.125-0.75 mg) orally once daily as compared with placebo for 6 weeks in patients with primary restless legs syndrome (RLS) and to investigate the reliability of the Japanese version of the RLS rating scale by the International Restless Legs Syndrome Study Group (IRLSSG) as a sub-study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. primary completion date: December 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

According to the essential diagnostic criteria for RLS of NIH and IRLSSG, the following four all criterias must be presented:

1. An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in legs

2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting

3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues

4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night

• PLM (during time in bed) index of at least 5 per hour (in the worst affected leg) at Visit 3

• Total score of RLS severity scale-Japanese version by IRLSSG > 15 at Visit 3

• At least 1 time per week of RLS symptoms interfering with sleep within the last one month at Visit 1.

Exclusion Criteria:

1. Pre-menopausal women who meet any one of the following (1) - (3):

• Pregnant or possibly pregnant

• In lactation

• Desire to be pregnant during study period Even when a patient was confirmed not to fall under the criteria above at initiation of study, if the patient is of childbearing potential, pregnancy tests should be performed when possible. If pregnancy test is positive, the investigational product should be discontinued.

2. Males not using an adequate form of contraception.

3. Patients who took the neuroleptics within 4 weeks before the screening Visit 1, or neuroleptic-induced akathisia.

4. Patients who can not stop the treatment with medication or dietary supplements, which could significantly influence RLS symptoms to wash-out at least 14 days before drug administration (refer to Appendix 3 for prohibited medication), e.g. dopaminergic drugs (levodopa or dopamine agonists) or antidopaminergic drugs (neuroleptics or metoclopramide etc.), MAO inhibitors, sympathomimetics, antidepressants, hypnotics, any benzodiazepines, antiepileptics, opioids, clonidine, magnesium, ferrous salts, folic acid, vitamin B12, antihistaminics, lithium, melatonin.

5. Patients with diabetes mellitus requiring insulin therapy.

6. Patients with microcytic anemia at investigators discretion.

7. History or clinical signs of peripheral neuropathy (PNP) of any origin in physical, neurological examination, myelopathy or multiple sclerosis or any other neurological disease, with potential to secondarily cause RLS symptoms.

8. Other sleep disorder, such as, REM sleep behaviour disorder, narcolepsy or sleep apnea syndrome (with AHI >15 at Visit 3, or a history of loud snoring occurring at least 5 nights a week combined with a history of breathing pauses during sleep and excessive daytime sleepiness).

9. Clinically significant renal disease or creatinine higher than upper limit of normal (ULN) at screening.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Psychomotor Agitation
• Restless Legs Syndrome
• Syndrome

Intervention

Drug:
• Pramipexole 0.125 mg tablets

• Pramipexole 0.125 mg tablets Placebo

Locations

Country	Name	City	State
Japan	Boehringer Ingelheim Investigational Site	Akita, Akita
Japan	Boehringer Ingelheim Investigational Site	Kochi, Kochi
Japan	Boehringer Ingelheim Investigational Site	Kurume, Fukuoka
Japan	Boehringer Ingelheim Investigational Site	Otaru,Hokkaido
Japan	Boehringer Ingelheim Investigational Site	Sakai, Osaka
Japan	Boehringer Ingelheim Investigational Site	Shibuya,Tokyo
Japan	Boehringer Ingelheim Investigational Site	Takatsuki, Osaka

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Endpoint: Decrease in periodic limb movements during time in bed index (PLMI) in the PSG
Secondary	Total score of RLS severity scale-J by IRLSSG, Periodic Limb Movements during Sleep Index (PLMSI) in the PSG Periodic Limb Movements during Wakefulness Index (PLMWI) in the PSG Periodic Limb Movements in Sleep with Arousal Index (PLMAI) in the PSG )

External Links

•   Link
•   Link